Search Result

Results for "

Crohn’s

" in MedChemExpress (MCE) Product Catalog:

By Targets:	15-PGDH (1) Antibiotic (4) Apoptosis (1) Autophagy (2) Bacterial (4) Bcl-2 Family (1) Caspase (1) CDK (1) CXCR (1) Drug Isomer (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (3) GCGR (2) Hedgehog (4) IFNAR (1) Integrin (1) Interleukin Related (3) Isotope-Labeled Compounds (4) JNK (1) MMP (1) mTOR (1) NO Synthase (1) p38 MAPK (2) Parasite (4) PI3K (1) Pregnane X Receptor (PXR) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) STAT (1) TGF-beta/Smad (1) TGF-β Receptor (1) TNF Receptor (2) β-catenin (1)
By Research Areas:	Cancer (7) Infection (5) Inflammation/Immunology (16) Metabolic Disease (3)

By Targets:

15-PGDH (1)

Antibiotic (4)

Apoptosis (1)

Autophagy (2)

Bacterial (4)

Bcl-2 Family (1)

Caspase (1)

CDK (1)

CXCR (1)

Drug Isomer (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (3)

GCGR (2)

Hedgehog (4)

IFNAR (1)

Integrin (1)

Interleukin Related (3)

Isotope-Labeled Compounds (4)

JNK (1)

MMP (1)

mTOR (1)

NO Synthase (1)

p38 MAPK (2)

Parasite (4)

PI3K (1)

Pregnane X Receptor (PXR) (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

STAT (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

TNF Receptor (2)

β-catenin (1)

By Research Areas:

Cancer (7)

Infection (5)

Inflammation/Immunology (16)

Metabolic Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-174990

HW201877	15-PGDH	Metabolic Disease Inflammation/Immunology
HW201877 is a potent and orally active 15-prostaglandin dehydrogenase (15-PGDH) inhibitor with an IC₅₀ of 3.6 nM. HW201877 demonstrates robust cellular efficacy in elevating PGE2 levels in A549 cells and exhibits remarkable efficacy in animal models of tissue injury and fibrosis. HW201877 can be used for the study of inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and Crohn’s disease (CD) .

HY-168990

Ontunisertib AGMB-129	TGF-β Receptor	Metabolic Disease Inflammation/Immunology Cancer
Ontunisertib (AGMB-129) is an orally active and selective gastrointestinal-restricted ALK5 (TGFβR1) inhibitor. Ontunisertib blocks signalling of the pro-fibrotic TGFβ pathway. Ontunisertib can be used for the research of fibrostenotic Crohn’s disease .

HY-130321

Lauroyl-L-carnitine chloride 1 Publications Verification	Endogenous Metabolite Interleukin Related	Inflammation/Immunology
Lauroyl-L-carnitine chloride is an orally active metabolite. Lauroyl-L-carnitine chloride significantly reverses the decrease in its target gene IL-10. Lauroyl-L-carnitine chloride alleviates Crohn' s-like colitis .

HY-115497

BRD5529 4 Publications Verification	E1/E2/E3 Enzyme	Infection Inflammation/Immunology
BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC₅₀ value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) .

HY-B0508

Ornidazole 2 Publications Verification Ro 7-0207	Bacterial Parasite Antibiotic Hedgehog	Infection Cancer
Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .

HY-P2221

Glepaglutide 1 Publications Verification ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P99325

Toralizumab IDEC-131; Anti-Human CD40 ligand Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .

HY-P99292

Fontolizumab HuZAF; Anti-Human IFNG Recombinant Antibody	IFNAR	Inflammation/Immunology
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .

HY-P2221B

Glepaglutide acetate 1 Publications Verification ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P99404

Quetmolimab E6011	CXCR	Inflammation/Immunology Cancer
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .

HY-130321S

Lauroyl-L-carnitine-d3 chloride	Isotope-Labeled Compounds Interleukin Related Endogenous Metabolite	Inflammation/Immunology
Lauroyl-L-carnitine-d₃ (chloride) is the deuterium labeled Lauroyl-L-carnitine chloride (HY-130321). Lauroyl-L-carnitine chloride is an orally active metabolite. Lauroyl-L-carnitine chloride significantly reverses the decrease in its target gene IL-10. Lauroyl-L-carnitine chloride alleviates Crohn' s-like colitis .

HY-172608

TNF-α-IN-24	TNF Receptor	Inflammation/Immunology
TNF-α-IN-24 (Example 15) is a TNF-α inhibitor with an IC₅₀ of 4.1 nM. TNF-α-IN-24 can be used in study of inflammatory and autoimmune disorders such as rheumatoid arthritis and Crohn’s disease .

HY-130321S1

Lauroyl-L-carnitine-d9 chloride	Isotope-Labeled Compounds Endogenous Metabolite Interleukin Related	Inflammation/Immunology
Lauroyl-L-carnitine-d₉ chloride is the deuterium labeled Lauroyl-L-carnitine chloride (HY-130321). Lauroyl-L-carnitine chloride is an orally active metabolite. Lauroyl-L-carnitine chloride significantly reverses the decrease in its target gene IL-10. Lauroyl-L-carnitine chloride alleviates Crohn' s-like colitis .

HY-B0508S1

Ornidazole-13C2,15N2 Ro 7-0207-¹³C₂,¹⁵N₂	Isotope-Labeled Compounds Bacterial Parasite Antibiotic Hedgehog	Infection
Ornidazole- ¹³C₂, ¹⁵N₂ is the ¹³C, ¹⁵N labeled Ornidazole. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .

HY-16151

CR-3294	Autophagy NO Synthase	Inflammation/Immunology Cancer
CR-3294 is an autophagy inducer in hypoxic cells. CR-3294 is an inducible enzyme nitric oxide synthase (iNOS) inhibitor. CR-3294 inhibits both the DNA binding of HIF-1alpha and VEGF mRNA synthesis. CR-3294 can be used for the study of breast cancer and inflammatory bowel disease (IBD), such as Crohn’s disease, ulcerative colitis .

HY-N2199

Sotetsuflavone	Apoptosis Autophagy PI3K JNK mTOR p38 MAPK CDK MMP TGF-beta/Smad STAT β-catenin Reactive Oxygen Species (ROS) Bcl-2 Family Caspase	Inflammation/Immunology Cancer
Sotetsuflavone is a flavonoid that can be isolated from Cycas revolute. Sotetsuflavone inhibits phosphorylation of PI3K, Akt, mTOR, JNK, and p38 MAPK; modulates expression of Cyclin D1, CDK4, Bcl-2, Bax, cleaved caspases 3/9, MMP-9, TGF-β, STAT3, and β-catenin. Sotetsuflavone induces G₀/G₁ cell cycle arrest, apoptosis, autophagy, and intracellular ROS elevation, inhibits cancer cell proliferation. Sotetsuflavone inhibits tumor growth in mouse tumor xenograft models. Sotetsuflavone can be used for the research of non-small cell lung cancer and Crohn’s disease .

HY-174300

Cholic acid-Glu	Pregnane X Receptor (PXR)	Metabolic Disease
Cholic acid-Glu is a derivative of Cholic acid (HY-N0324). The abundance of Cholic acid-Glu is increased in Crohn’s disease. Cholic acid-Glu increases PXR activation and significantly increases the expression of the downstream PXR target gene Cyp3a11 in small intestinal organoid tissue .

HY-B0508S

Ornidazole-d5 Ro 7-0207-d₅	Isotope-Labeled Compounds Bacterial Parasite Antibiotic Hedgehog	Infection Cancer
Ornidazole-d₅ is deuterium labeled Ornidazole. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .

HY-B0508R

Ornidazole (Standard) Ro 7-0207 (Standard)	Reference Standards Bacterial Parasite Antibiotic Hedgehog	Infection Cancer
Ornidazole (Standard) is the analytical standard of Ornidazole. This product is intended for research and analytical applications. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease .

HY-175433

p38 MAPK-IN-10	p38 MAPK	Inflammation/Immunology
p38 MAPK-IN-10 (Compound 4) is an orally active and potent p38 MAP kinase inhibitor (IC₅₀=570 nM). p38 MAPK-IN-10 is promising for research of chronic inflammatory diseases such as rheumatoid arthritis and Crohn’s disease .

HY-186079A

(S)-Deethyl-emvistegrast	Drug Isomer Integrin	Inflammation/Immunology
(S)-Deethyl-emvistegrast is the S-enantiomer of Deethyl-emvistegrast (HY-186079). Deethyl-emvistegrast is a quinoline derivative and also a α4β7 integrin inhibitor. It acts as the hydrolysis product of Emvistegrast (HY-177080). Deethyl-emvistegrast modulates inflammatory pathways and can be used in research related to inflammatory bowel diseases (Crohn's disease and ulcerative colitis) .

Cat. No.	Product Name	Target	Research Area